Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapeutic experience with cilazapril

J H Rosenthal1

  • 1Section of Pharmacotherapy, Ulm University Medical Center, Germany.

Journal of Cardiovascular Pharmacology
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interaction of spatial perception, vestibular function, and exercise in young school age boys with learning disabilities.

Perceptual and motor skills·1989
Same author

Hemodynamic and endocrine responses to guanfacine in normotensive volunteers and hypertensive patients.

The American journal of cardiology·1986
Same author

Investigations of components of the renin-angiotensin system in rat vascular tissue.

Hypertension (Dallas, Tex. : 1979)·1984
Same author

The visual ERP predicts clinical response to methylphenidate in hyperactive children.

Psychophysiology·1984
Same author

Averaged evoked potential predictors of clinical improvement in hyperactive children treated with methylphenidate: an initial study and replication.

Psychophysiology·1976
Same author

Right cervical aortic arch with left descending aorta. Case report and review of the literature.

American journal of diseases of children (1960)·1969
Same journal

Integration of Mendelian Randomization and FAERS Database Analysis Reveals the Association Between Ergotamine and Aortic and Mitral Valve Diseases.

Journal of cardiovascular pharmacology·2026
Same journal

A Comprehensive Review of PCSK9 Inhibitor Therapy.

Journal of cardiovascular pharmacology·2026
Same journal

SGLT2 Inhibitors and Progression of Chronic Kidney Disease in Patients with Elevated Lipoprotein(a): A Real-World Cohort Study.

Journal of cardiovascular pharmacology·2026
Same journal

Aspirin in primary prevention: a case for selective use.

Journal of cardiovascular pharmacology·2026
Same journal

GLP-1 Gene Therapy Trial for Obesity and Type 2 Diabetes: Towards a New Paradigm for Chronic Disease Treatment.

Journal of cardiovascular pharmacology·2026
Same journal

Expert Opinion: Restrictions, Precautions, or Normalcy? Defining Everyday Risk in Patients Treated With IL-1 Blockers for Recurrent Pericarditis.

Journal of cardiovascular pharmacology·2026
See all related articles

Cilazapril, an angiotensin-converting enzyme (ACE) inhibitor, effectively lowers blood pressure and reduces left ventricular mass in hypertensive patients. It also shows potential benefits for glucose tolerance and renal function with side effects comparable to other ACE inhibitors.

Area of Science:

  • Cardiology
  • Pharmacology
  • Nephrology

Background:

  • Hypertension is a significant risk factor for cardiovascular and renal diseases.
  • Left ventricular hypertrophy (LVH) is a common complication of hypertension.
  • Angiotensin-converting enzyme (ACE) inhibitors are a class of drugs used to treat hypertension.

Purpose of the Study:

  • To evaluate the efficacy and safety of cilazapril in patients with mild-to-moderate hypertension.
  • To assess the impact of cilazapril on hemodynamic parameters, left ventricular mass, glucose tolerance, insulin sensitivity, and renal function.

Main Methods:

  • Open-label, long-term observational studies.
  • Hemodynamic investigations.
  • Assessment of left ventricular mass index, glucose tolerance, insulin sensitivity, and renal function.

Related Experiment Videos

Main Results:

  • Cilazapril controlled blood pressure (≤90 mm Hg) within 2-3 weeks at 2.5-5.0 mg daily, with sustained effect over 1 year.
  • Antihypertensive action was attributed to decreased peripheral vascular resistance and pulmonary capillary wedge pressure.
  • Cilazapril reduced left ventricular mass index within 6 months, reversing LVH.
  • Improved glucose tolerance and insulin sensitivity in nondiabetic patients; enhanced renal function in diabetic patients.
  • Side effect profile was comparable to other ACE inhibitors.

Conclusions:

  • Cilazapril is an effective antihypertensive agent with favorable effects on cardiac structure and metabolic parameters.
  • It offers a comparable safety profile to existing ACE inhibitors.
  • Further long-term studies are needed to confirm potential vascular and antiatherosclerotic benefits.